Pages that link to "Q36535994"

The following pages link to IMPDH activity in thiopurine-treated patients with inflammatory bowel disease - relation to TPMT activity and metabolite concentrations (Q36535994):

Displaying 25 items.

• The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease (Q28279791) (← links)
• Gene expression and thiopurine metabolite profiling in inflammatory bowel disease - novel clues to drug targets and disease mechanisms? (Q28486322) (← links)
• New genetic biomarkers predicting azathioprine blood concentrations in combination therapy with 5-aminosalicylic acid (Q28538238) (← links)
• Monitoring thiopurine metabolites in korean pediatric patients with inflammatory bowel disease (Q33941619) (← links)
• Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose (Q34549324) (← links)
• Accuracy of genotyping using the TaqMan PCR assay for single nucleotide polymorphisms responsible for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. (Q36230695) (← links)
• Combination treatment with 6-mercaptopurine and allopurinol in HepG2 and HEK293 cells - Effects on gene expression levels and thiopurine metabolism (Q36302849) (← links)
• Pharmacogenomics in the treatment of inflammatory bowel disease (Q37710516) (← links)
• Novel strategies in the thiopurine treatment of inflammatory bowel disease. (Q37764761) (← links)
• Thiopurines in Crohn's disease, is there something new? (Q37797517) (← links)
• Pharmacogenetic determinants of mercaptopurine disposition in children with acute lymphoblastic leukemia (Q37994062) (← links)
• Monitoring and safety of azathioprine therapy in inflammatory bowel disease. (Q38134756) (← links)
• Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. (Q38417177) (← links)
• Genetic variants in 6-mercaptopurine pathway as potential factors of hematological toxicity in acute lymphoblastic leukemia patients (Q39047242) (← links)
• Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine. (Q40582133) (← links)
• Tolerability and usefulness of mercaptopurine in azathioprine-intolerant Japanese patients with ulcerative colitis (Q42774560) (← links)
• Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping (Q47344295) (← links)
• Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring (Q57817595) (← links)
• Hypoxanthine guanine phosphoribosyltransferase activity is related to 6-thioguanine nucleotide concentrations and thiopurine-induced leukopenia in the treatment of inflammatory bowel disease (Q83550487) (← links)
• Effect of genetic polymorphisms on effectiveness of low-dose azathioprine in Japanese patients with systemic lupus erythematosus (Q85504050) (← links)
• NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease (Q86757273) (← links)
• Precision therapy of 6-mercaptopurine in Chinese children with acute lymphoblastic leukaemia (Q89796175) (← links)
• Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy (Q91667005) (← links)
• New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer via small molecule potentiators (Q92702329) (← links)
• Tests that now deserve to be more widely adopted in IBD clinical practice (Q98386278) (← links)